Ivermectin Versus Standard Treatment in Mild COVID-19
Covid19
About this trial
This is an interventional treatment trial for Covid19 focused on measuring COVID-19, Ivermectin, Standard therapy, ICU admission, Clinical improvement, Side effects, Effectiveness
Eligibility Criteria
Inclusion Criteria:
- Confirmed mild cases of COVID-19 defined as: symptomatic patients with any of COVID-19 symptoms (fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell),
- In addition to absolute leucopoenia (< 4000) / absolute lymphopenia (< 1000), positive CRP (C-reactive protein), high serum ferritin and/or positive PCR for SARS-CoV-2 in nasopharyngeal swab.
- no dyspnea and no abnormalities on high resolution chest imaging (HRCT).
- Patients should be at home (not admitted to hospital) with no supplemental oxygen treatment.
Exclusion Criteria:
• Asymptomatic patients
- Dyspnoea or abnormalities on chest imaging
- Hospital admission
- Severe pneumonia
- Impairment in liver functions
- Received Ivermection in the last 5 days before being included in the study.
- Pregnancy is an exclusion criterion
Sites / Locations
- Aliae AR Mohamed-Hussein
Arms of the Study
Arm 1
Arm 2
Active Comparator
Other
Group 1: Ivermectin + standard treatment
Group-2: Standard treatment only
Patients will receive 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard treatment (Azithromycin 500mg once daily for 5 days, Paracetamol 500mg every 8 hours, vitamin C 1gm once daily, Zinc 50 mg once daily, Lactoferrin 100mg sachets twice daily and prophylactic or therapeutic anticoagulation if D-dimer is elevated.
This group will receive the standard treatment protocol as outlined above according to the Egyptian Ministry of Health protocol of treating cases with mild COVID-19.